$27.71 Million in Sales Expected for Spark Therapeutics Inc (NASDAQ:ONCE) This Quarter
Brokerages forecast that Spark Therapeutics Inc (NASDAQ:ONCE) will post sales of $27.71 million for the current quarter, Zacks reports. Two analysts have issued estimates for Spark Therapeutics’ earnings, with estimates ranging from $26.92 million to $28.50 million. Spark Therapeutics reported sales of $25.19 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 10%. The business is scheduled to report its next quarterly earnings results on Tuesday, August 27th.
According to Zacks, analysts expect that Spark Therapeutics will report full-year sales of $119.12 million for the current year, with estimates ranging from $72.80 million to $157.06 million. For the next financial year, analysts expect that the company will report sales of $139.14 million, with estimates ranging from $137.00 million to $141.27 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Spark Therapeutics.
Several equities analysts have recently commented on ONCE shares. Mizuho restated a “hold” rating and issued a $114.50 price objective on shares of Spark Therapeutics in a report on Monday, August 12th. Zacks Investment Research lowered shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $87.92.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP increased its holdings in shares of Spark Therapeutics by 1,378.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 124,712 shares of the biotechnology company’s stock valued at $4,881,000 after purchasing an additional 116,277 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of Spark Therapeutics by 36.7% in the 4th quarter. Legal & General Group Plc now owns 14,083 shares of the biotechnology company’s stock valued at $551,000 after purchasing an additional 3,782 shares in the last quarter. Norges Bank purchased a new position in shares of Spark Therapeutics in the 4th quarter valued at about $7,309,000. Geode Capital Management LLC increased its holdings in shares of Spark Therapeutics by 9.9% in the 4th quarter. Geode Capital Management LLC now owns 370,000 shares of the biotechnology company’s stock valued at $14,481,000 after purchasing an additional 33,414 shares in the last quarter. Finally, Meeder Asset Management Inc. purchased a new position in shares of Spark Therapeutics in the 1st quarter valued at about $121,000. 81.40% of the stock is currently owned by hedge funds and other institutional investors.
About Spark Therapeutics
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.
Further Reading: Cost of Capital Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.